Treatment of Anxiety-Induced Erectile Dysfunction in Adult Males

First-Line Treatment Approach

The American Urological Association recommends that men with anxiety-induced erectile dysfunction should be offered FDA-approved oral phosphodiesterase type 5 inhibitors (PDE5i) as first-line therapy, combined with psychotherapy or psychosexual counseling to address the underlying psychological factors 1, 2

PDE5i therapy should be initiated regardless of whether ED has psychological or physical origins, starting with conservative dosing and titrating to maximum dose as needed 3
Sildenafil, tadalafil, vardenafil, or avanafil are all appropriate first-line options, with weighted mean success rates of 68-69% for achieving successful intercourse compared to 33-35% with placebo 3
An adequate trial requires at least 5-6 separate occasions at maximum dose before declaring treatment failure 3

Psychotherapy should be offered as an adjunct to medical treatment, not as an alternative, to optimize therapeutic outcomes 1, 2
The presence of nocturnal and/or morning erections suggests (but does not confirm) a psychogenic component that would benefit from psychotherapy 1
Psychotherapy should integrate psychodynamic, systematic, behavioral, and cognitive approaches within a short-term model, delivered in individual, couples, group, or online formats 4, 5

Identify specific psychogenic features including sudden onset of symptoms, early collapse of erection during intercourse, preserved quality of morning, spontaneous, or self-stimulated erections, and situational factors 1, 2, 3
Screen for psychological factors that may be primary or secondary contributors, such as depression, generalized anxiety, relationship conflict, diminished self-esteem, and history of sexual abuse 1, 2, 5

Measure morning serum total testosterone in all men with ED (testosterone deficiency defined as total testosterone <300 ng/dL with symptoms) 1, 2, 3
Consider fasting glucose/HbA1c and lipid profile to evaluate cardiovascular risk factors, as ED is a risk marker for cardiovascular disease 1, 2

ED in men over 30 years should be considered a risk marker for underlying cardiovascular disease, requiring appropriate counseling and cardiovascular risk factor assessment 1, 2
The presence of ED is as strong a predictor of future cardiac events as cigarette smoking or family history of myocardial infarction 1

Implement concurrent lifestyle modifications including smoking cessation, weight loss if BMI >30 kg/m², increased physical activity, reduced alcohol consumption, and optimization of comorbid conditions 2, 3, 5

Combining behavioral/psychological approaches with pharmacological treatment is more effective than either modality alone 4
Combination therapy leads to significantly greater increases in ejaculatory latency time and improvement on validated assessment instruments compared to pharmacological therapy alone 4

After failure of two different PDE5i trials at maximum dose, refer to urology for further evaluation and treatment 3

Absolute contraindication: concurrent use with nitrates (regular or intermittent organic nitrates) 3
Educate patients that if anginal chest pain occurs after taking PDE5i, they must seek immediate medical attention and inform providers that at least 48 hours must elapse after the last PDE5i dose before nitrate administration 3

Do not overlook medication-induced ED; review all current medications and consider alternatives with lower ED risk 2
Do not assume absence of organic pathology based solely on presence of nocturnal erections; this suggests but does not confirm purely psychogenic ED 1
Do not neglect partner involvement; thoughtful discussion with both patient and partner promotes acceptance of treatment and improves outcomes 1
Do not declare PDE5i treatment failure prematurely; ensure adequate trial of at least 5-6 occasions at maximum dose with proper dosing instructions 3